Control of heart rate during transition from intravenous to oral diltiazem in atrial fibrillation or flutter.

We tested whether patients presenting with atrial fibrillation (AF) or flutter (AFl) with a rapid ventricular response could maintain control of heart rate while transferring from a bolus and continuous infusion of intravenous diltiazem to oral diltiazem. Forty patients with AF or AFI and sustained ventricular rate > or = 120 beats/min received intravenous diltiazem "bolus" (20 to 25 mg for 2 minutes) and "infusion" (5 to 15 mg/hour for 6 to 20 hours). Oral long-acting diltiazem (diltiazem CD 180, 300, or 360 mg/24 hours) was administered in patients in whom stable heart rate control was attained during constant infusion. Intravenous diltiazem infusion was discontinued 4 hours after the first oral dose, and patients were monitored during 48 subsequent hours of "transition" to oral therapy. Response to diltiazem was defined as heart rate <100 beats/min, > or = 20% decrease in heart rate from baseline, or conversion to sinus rhythm. Other rate control or antiarrhythmic medications were not allowed during the study period. Thirty-seven of 40 patients maintained heart rate control during the bolus, and 35 of the remaining 37 maintained control during the infusion of intravenous diltiazem. Of the 35 patients achieving heart rate control with intravenous diltiazem who entered the transition to oral therapy, 27 maintained heart rate control (response rate of 77%/, 95% confidence interval 63% to 91%). The median infusion rate of intravenous diltiazem was 10 mg/hour, and the median dose of oral diltiazem CD was 300 mg/day. Oral long-acting diltiazem was 77% effective in controlling ventricular response over 48 hours in patients with AF or AFl in whom ventricular response was initially controlled with intravenous diltiazem.

Improved detection of silent cardiac ischemia with a 12-lead portable microprocessor-driven real-time electrocardiographic monitor.

OBJECTIVE: To compare a microprocessor-driven real-time 12-lead electrocardiographic monitoring device with Holter monitoring for detection of ischemia. DESIGN: Electrocardiographic monitoring was conducted in 110 patients at bed rest or undergoing surgical procedures. MATERIAL AND METHODS: In three groups of patients, simultaneous monitoring with a 12-lead real-time device and a 2-channel Holter system was performed to detect ischemic episodes. The differences in the number of ischemic events and the total time of ischemia revealed by the two devices were analyzed statistically. RESULTS: In patients with coronary artery disease, more ischemic ST-segment shifts were detected by the 12-lead device than by Holter monitoring (44 versus 16 events; P < 0.05). Total time of ischemia was also greater with the 12-lead device (879 versus 273 minutes; P < 0.05). Ischemia was detected by both techniques in 6 patients, only by the 12-lead device in 12, and only by Holter monitoring in 1. Neither device detected ischemia in control subjects. The 12-lead device had an advantage in detecting inferior ischemia, and it identified an additional 13 patients with unstable angina who had changes in T-wave polarity but did not exhibit ST-segment shifts. CONCLUSION: The 12-lead real-time electrocardiographic monitoring device is superior to Holter monitoring in detecting and facilitating real-time identification of myocardial ischemia in patients at bed rest.

Older adults living with chronic pain: an opportunity for improvement.

The American Geriatrics Society has recently published clinical practice guidelines addressing chronic pain in older adults. The guidelines identify current provider-based and system-oriented barriers and recommend practice improvements to enhance routine assessment, pharmacological therapy, and nonpharmacological therapy. Recommended organizational improvements focus on facilitating access and delivery of optimal care for all older adults living with chronic pain. Nurses are encouraged to assess older adults routinely for the presence of chronic pain and to advocate for appropriate treatment when indicated.

Proving that less is more: linking resources to outcomes.

Advocates of inpatient managed care employing clinical pathways are confident that this patient management strategy reduces cost while promoting optimal patient outcomes. Other health care professionals are concerned that cost reductions place patients at higher risk for adverse health events. Research is needed to demonstrate the true impact of cost-containment strategies on clinical outcomes. The article describes a study in progress comparing patients conventionally managed by their physicians with similar patients whose overall management involved a nurse case manager. This study explores the issue of resource costs that can be linked to clinical and financial outcome measures.